Prospective, double blind, randomized, controlled trial of simvastatin in human fracture healing

Journal of Orthopaedic Research

Volumn 27, Issue 3, 2009, Pages 281-285

  Patil, Sanjeev ^a   Holt, Graeme ^b   Raby, Nigel ^b   McLellan, Alastair R ^b   Smith, Karen ^c   O'Kane, Sarah ^c   Beastall, Graham ^c   Crossan, James F ^b  

^a SOUTHERN GENERAL HOSPITAL   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

^c NHS Greater Glasgow and Clyde Clinical Biochemistry Service   (United Kingdom)

Author keywords

Fracture healing; Osteoporosis; Radius; Statin

Indexed keywords

PLACEBO; SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; DOUBLE BLIND PROCEDURE; DUAL ENERGY X RAY ABSORPTIOMETRY; FOLLOW UP; FRACTURE HEALING; HUMAN; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; METAPHYSIS; PRIORITY JOURNAL; RADIUS FRACTURE; RANDOMIZED CONTROLLED TRIAL; SCANNING ELECTRON MICROSCOPY; DRUG EFFECT; FEMALE; MALE; MIDDLE AGED; PROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; DOUBLE-BLIND METHOD; FEMALE; FRACTURE HEALING; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RADIUS FRACTURES; SIMVASTATIN;

EID: 62249223586     PISSN: 07360266     EISSN: None     Source Type: Journal    
DOI: 10.1002/jor.20572     Document Type: Article

References (20)

1. Praemer A, Furner S, Rice DP. 1999. Musculoskeletal Conditions in the United States. Rosemong, Il: American Academy of Orthopaedic Surgeons.
2. Heckman JD, Sarasohn-Kahn J. 1997. The economics of treating tibia fractures. The cost of delayed unions. Bull Hosp Joint Dis 56:63-72.
3. Bostrom MP. 1998. Expression of bone morphogenetic proteins in fracture healing. Clin Orthop 355:116-123.
4. Bourque WT, Gross M, Hall BK. 1993. Expression of four growth factors during fracture repair. Int J Dev Biol 37:573-579.
5. Joyce ME, Jingushi S, Bolander ME. 1990. Transforming growth factor-beta in the regulation of fracture repair. Orthop Clin North Am 21:199-209.
6. Plosker GL, McTavish D. 1995. Simvastatin: a reappraisal of its pharmacological properties and therapeutic efficacy. Drugs 50:334-363.
7. Scandinavian Simvastatin Survival Study Group. 1994. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389.
8. Mundy G, Gaarrett R, Harris S, et al. 1999. Stimulation of bone formation in vitro and in rodents by statins. Science 286:1946-1949.
9. Skoglund B, Forslund C, Aspenberg P. 2002. Simvastatin improves fracture healing in mice. J Bone Miner Res 17:2004-2008.
10. Oxlund H, Dalstra M, Andreassen TT. 2001. Statin given perorally to adult rats increases cancellous bone mass and compressive strength. Calcif Tissue Int 69:299-304.
11. Chen D, Harris MA, Rossini G, et al. 1997. Bone morphogenetic protein 2 (BMP-2) enhances BMP-3, BMP-4, and bone cell differentiation marker gene expression during the induction of mineralized bone matrix formation in cultures of fetal rat calvarial osteoblasts. Calcif Tissue Int 60:283-290.
12. Veitch SW, Findlay SC, Hamer AJ, et al. 2006. Changes in bone mass and bone turnover following tibial shaft fracture. Osteoporos Int 17:364-372.
13. Sinzinger H, Wolfram R, Peskar BA. 2002. Muscular side effects of statins. J Cardiovas Pharmacol 40:163-171.
14. Kristiansen TK, Ryaby JP, McCabe JRN, et al. 1997. Accelerated Healing of Distal Radial Fractures with the Use of Specific, Low-Intensity Ultrasound. A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Study. J Bone J Surg 79-A:961-973.
15. Meier CR, Schlienger RG, Kraenzlin ME, et al. 2000. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 283:3205-3210.
16. Wang PS, Solomon DH, Mogun H, et al. 2000. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 283:3211-3216.
17. van Staa TP, Wegman S, de Vries F, et al. 2001. Use of Statins and Risk of Fractures. JAMA 285:1850-1855.
18. Chung YS, Lee MD, Lee SK, et al. 2000. HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J Clin Endocrinol Metab 85:1137-1142.
19. Bauer SDC, Mundy GR, Jamal SA, et al. 1999. Statin use, bone mass and fracture: an analysis of two prospective studies. J Bone Miner Res 14:S179.
20. Hamelin BA, Turgeon J. 1998. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci 19:26-37.